• 목록

Hyperthermia Emerges as a New Cancer Treatment at International Academic Conference

On November 25, from 9:00 AM to 6:00 PM, the 5th IVRA (International Virus Research Alliance) International Conference was held at the Le Méridien Hotel in Cyberjaya, Malaysia. The conference was a resounding success, attended by more than 250 distinguished cancer specialists from Malaysia, India, Singapore, and other Southeast Asian countries, as well as members and organizers of IVRA from Korea. The event also drew participation from Malaysian government officials, broadcasting representatives, and medical professionals from over ten countries, all of whom shared and discussed clinical results of cancer treatment using high-frequency hyperthermia, generating significant interest among the medical community.

From Korea, prominent participants included:

·         Prof. Hong-Seok Jang and Prof. Young-Nam Kang (Department of Radiation Oncology, Seoul St. Mary’s Hospital)

·         Prof. Kang-Hyun Lee (Former Dean, Wonju Severance Christian Hospital)

·         Dr. Seung-Mo Yoo (Chairman, IVRA Organizing Committee; Director, Yesan Myongji Hospital)

·         Dr. Eui-Shin Kim (Lifetime Professor of Radiation Oncology, MD Anderson Cancer Center, USA)

·         Dr. Sang-Keun Jang (Director, Konkuk University Hospital)

·         Dr. Seon-Man Kim (Director, Amilang Clinic, Suwon)

In addition, more than 50 Korean medical experts from both Western and traditional Korean medicine joined the event. Around 20 speakers and moderators from Korea and abroad led the sessions. Notable international scholars included Dr. Ho Gwo Fuang, Dr. Kenny Yong Yean Sirn, Dr. Zawawi Abdullah, Kalaiarasu Malayandi (Chairman of Cyberjaya University), Dr. Paramjit Kaur, Dr. Damodara Kumaran, Dr. Nagraj G. Huilgol, and Dr. N.R. Datta.

At the heart of this academic conference was AdipoLabs, Inc., the official corporate partner of IVRA, which has consistently exported and donated the Remission 1℃ high-frequency hyperthermia cancer treatment device to IVRA member countries for cancer treatment and clinical research. As a result, oncologists worldwide have continuously published clinical papers and case reports on the effectiveness of this therapy, which were shared and discussed at this year’s international conference.

More than 20 presentations were delivered on the use of hyperthermia therapy in cancer treatment. A panel discussion led by Prof. Hong-Seok Jang, Dr. Nagraj G. Huilgol, Dr. Ho Gwo Fuang, and Dr. N.R. Datta provided diverse perspectives on the future of hyperthermia in oncology.

As a medical association originally formed during the COVID-19 pandemic, IVRA has continued to grow in both scope and depth with each conference. This international gathering in Malaysia proved to be a meaningful milestone, offering IVRA member physicians from around the world a platform to present new directions for the future of cancer treatment.

Sung-Ho Han, CEO of AdipoLabs, Inc., developer and manufacturer of Remission 1℃, stated:

“The clinically proven effectiveness of Remission 1℃, presented at this prestigious international conference, delivered a message of hope to cancer patients worldwide. This event also marked an opportunity to elevate the global status of Korean medical technology.”

The conference was co-sponsored by the Korean Society of Hyperthermia in Medicine, Wonju Severance Christian Hospital, Korean Emergency Medical Association, and Korean Balance Medical Society.